News

Amneal Pharmaceuticals is seeking U.S. approval of IPX-203, its extended-release carbidopa-levodopa (CD/LD) tablets, for Parkinson’s disease. The company submitted an Investigational New Drug Application to the Food and Drug Administration (FDA), which is based on top-line data from the Phase 3 RISE-PD clinical trial that showed IPX-203…

A dozen runners who live with Parkinson’s disease (PD) hope to heighten awareness of the neurodegenerative disorder and raise funds for research by taking on one of the nation’s most demanding relay road races — the Blue Ridge Relay — on Sept. 9-10. The 12 runners, who’ve dubbed themselves…

Screening a large database with machine learning tools helped scientists identify approved medicines for other diseases that reduced the risk of developing Parkinson’s, a study reported. According to researchers, these potential Parkinson’s disease therapies “deserve to be confirmed” in larger studies. “Drug repurposing or repositioning is the application of…

In-home, non-contact sensors that can identify changes in movement and behaviors may allow age-related diseases, including Parkinson’s, to be detected early, a study reports. By using machine learning tools, the study shows how outcomes such as fall risk, frailty, and cognitive abilities may be assessed in a home setting.

Mirapex (pramipexole) improved the quality of life for people with Parkinson’s disease compared to a placebo, according to a pooled analysis of several clinical trials. Quality of life improvements were seen regardless of disease stage, duration of treatment, or quality of life assessments before treatment. This analysis provided new…

In a webinar hosted by AC Immune, scientists discussed the various advantages of vaccines — ranging from their expected safety and long-lasting immune responses to potentially lower costs — in treating and possibly preventing Parkinson’s and Alzheimer’s disease. The “Key Opinion Leader” webinar, broadcasted on Aug.

Exercise can modify the connectivity of the brain’s pedunculopontine nucleus (PPN) with other areas of the brain in people with Parkinson’s disease and gait impairments, a study has found. Decreases in connectivity of the PPN on the left side of the brain after exercise were associated with motor improvements…

The University of Oxford Parkinson’s Disease Centre is working with Metabolon to identify metabolic biomarkers of Parkinson’s risk and progression that could lead to tailored disease treatments and better patient care. “Metabolon’s highly accurate data will enable the identification of metabolomic biomarkers crucial to understanding and better predicting…

Two nonprofits have joined in an international partnership to accelerate the development of therapies for Parkinson’s disease (PD), a neurodegenerative condition thought to affect 10 million people globally. The Parkinson’s Foundation will invest at least $3 million over the next three years in Parkinson’s Virtual Biotech, the treatment development arm…

The first patient has been dosed in a clinical trial testing Annovis Bio’s buntanetap as an oral therapy for early-stage Parkinson’s disease, the company announced. The Phase 3 clinical trial (NCT05357989) got started shortly after the U.S. Food and Drug Administration (FDA) gave the company the…